Prediction of Prognosis Following Fludarabine Used as Secondary Therapy for Chronic Lymphocytic Leukemia

References

• Boggs DR, Sofferman SA, Wintrobe MM, Cartwright GE. Factors influencing the duration of survival of patients with chronic lymphocytic leukemia. Am J Med 1966; 40: 243
   PubMed Web of Science ®Google Scholar
• Dameshek W. Chronic lymphocytic leukemia - An accumulative disease of immunologically incompetent lymphocytes. Blood 1967; 29: 566
   PubMed Web of Science ®Google Scholar
• Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternak BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219
   PubMed Web of Science ®Google Scholar
• Binet JL, Leporrier M, Dighiero G, Charron D, D'Athis Ph., Vaugier G, Merle Beral H, Natali JC, Raphael M, Nizet B, Follezou JY. A clinical staging system for chronic lymphocytic leukemia. Prognostic significance. Cancer 1977; 40: 855
   PubMed Web of Science ®Google Scholar
• Jaksic B, Vitale B. Total tumour mass score (TIM): A new parameter in chronic lymphocytic leukemia. Br J Haematol 1981; 49: 405
   PubMed Web of Science ®Google Scholar
• Lee JS, Dixon DO, Kantarjian HM, Keating MJ, Talpaz M. Prognosis of chronic lymphocytic leukemia: A multivariate regression analysis of 325 untreated patients. Blood 1987; 69: 929
   PubMed Web of Science ®Google Scholar
• Mandelli F, De Rossi G, Mancini P, Alberti A, Cajozzo A, Grignani F, Leoni P, Liso V, Martelli M, Neri A, Resegotti L, Torlontano G. Prognosis in chronic lymphocytic leukemia: A retrospective multicentric study from the GIMEMA group. J Clin Oncol 1987; 5: 398
   PubMed Web of Science ®Google Scholar
• Cheson BD. Chronic lymphocytic leukemia: Staging and prognostic factors. Chronic Lymphocytic Leukemia: Scientific Advances and Clinical Developments, BD Cheson, New York 1993
   Google Scholar
• Keating MJ, Scouros M, Murphy S, Kantarjian H, Hester J, McCredie KB, Hersh EM, Freireich EJ. Multiple agent chemotherapy (POACH) in previously treated and untreated patients with chronic lymphocytic leukemia. Leukemia 1988; 2: 157
   PubMed Web of Science ®Google Scholar
• Montserrat E, Alcala A, Alonso C, Besalduch J, Moraleda JM, Garcia-Conde J, Gutierrez M, Gomis F, Garijo J, Guzman MC, Estape J, Rozman C. and participating members of Pethema, Spanish Society of Hematology: A randomized trial comparing chlorambucil plus prednisone vs cyclophosphamide, melphalan, and prednisone in the treatment of chronic lymphocytic leukemia stages B and C. Nouv Rev Fr Hematol 1988; 30: 429
   PubMed Web of Science ®Google Scholar
• Grever MR, Kopecky KJ, Coltman CA, Files JC, Greenberg BR, Hutton JJ, Talley R, Von Hoff DD, Balcerak SP. Fludarabine monophosphate: A potentially useful agent in chronic lymphocytic leukemia. Nouv Rev Fr Hematol 1988; 30: 457
   PubMedGoogle Scholar
• Keating MJ, Kantarjian H, Talpaz M, Redman J, Koller C, Barlogie B, Velasquez W, Plunkett W, Freireich EJ, McCredie KB. Fludarabine: A new agent with major activity against chronic lymphocytic leukemia. Blood 1989; 74: 19
   PubMed Web of Science ®Google Scholar
• O'Brien S, Kantarjian H, Beran M, et al. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis derived prognostic model for response to treatment. Blood 1993; 82: 1695
   PubMed Web of Science ®Google Scholar
• Kemena A, O'Brien S, Kantarjian H, et al. Phase Ii clinical trial of fludarabine in chronic lymphocytic leukemia on a weekly low-dose schedule. Leuk Lymph 1993; 10: 187
   PubMed Web of Science ®Google Scholar
• Robertson LE, O'Brien S, Koller C, et al. A three-day schedule of fludarabine in chronic lymphocytic leukemia (CLL). Blood, in press
   Google Scholar
• Cheson BD, Bennett JM, Rai KR, Grever MR, Kay NE, Schiffer CA, Oken MM, Keating MJ, Boldt DH, Kempin SJ, Foon KA. Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group. Am J Hematol 1988; 29: 152
   PubMed Web of Science ®Google Scholar
• Cox DR. Regression models in life tables. J Royal Statistical Society (B) 1972; 34: 187–220
   Web of Science ®Google Scholar
• Cox DR, Snell EJ. Analysis of Binary Data. 2nd ed. Chapman and Hall, New York 1989
   Google Scholar
• Harrell FE, Lee KL, Califf RM, Pryor DB, Rosati RA. Regression modelling strategies for improved prognostic prediction. Statistics in Medicine 1984; 3: 143–152
   PubMed Web of Science ®Google Scholar
• Kempin S, Lee BH, III, Thaler HT, Koziner B, Hecht S, Gee T, Arlin Z, Little C, Straus D, Reich L, Phillips E, Al-Mondhiry H, Dowling M, Mayer K, Clarkson B. Combination chemotherapy of advanced chronic lymphocytic leukemia: The M-2 protocol (vincristine, BCNU, cyclophosphamide, melphalan and prednisone). Blood 1982; 60: 1110
   PubMed Web of Science ®Google Scholar
• Saven A, Lemon RH, Kosty M, et al. 2-chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. Blood, in press
   Google Scholar
• Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: A phase II trial of cancer and leukemia group B. J Clin Oncol 1989; 7: 433
   PubMed Web of Science ®Google Scholar
• Gaidano G, Ballerini P, Gong JZ, et al. P53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 1991; 88: 5413
   PubMed Web of Science ®Google Scholar
• El Rouby S, Thomas A, Costin D, et al. P53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 1993; 82: 3452
   PubMed Web of Science ®Google Scholar
• Malspeis L, Grever MR, Staubus AE, Young D. Pharmacokinetics of 2-F-ara-A (9-β-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigations of fludarabine phosphate. Sem Oncol 1990; 17(8)18–32
   PubMedGoogle Scholar